Search Results
Search for other papers by Jesús Morillo-Bernal in
Google Scholar
PubMed
Molecular Oncology Group, IMDEA Food Institute, CEI UAM-CSIC, Madrid, Spain
Search for other papers by Lara P Fernández in
Google Scholar
PubMed
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
Search for other papers by Pilar Santisteban in
Google Scholar
PubMed
-specific proteins and differentiation markers is common in thyroid carcinogenesis. Indeed, several studies have reported the abnormal expression of thyroid-specific transcription factors in some thyroid carcinomas and propose that their deregulation is a pivotal
Department of Paediatric Endocrinology, Barts Health NHS Trust, London, UK
Search for other papers by Sasha R Howard in
Google Scholar
PubMed
Search for other papers by Sarah Freeston in
Google Scholar
PubMed
Search for other papers by Barney Harrison in
Google Scholar
PubMed
Search for other papers by Louise Izatt in
Google Scholar
PubMed
Search for other papers by Sonali Natu in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Sabine Pomplun in
Google Scholar
PubMed
Search for other papers by Helen A Spoudeas in
Google Scholar
PubMed
Search for other papers by Sophie Wilne in
Google Scholar
PubMed
Department of Paediatric Endocrine Surgery, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
Search for other papers by Tom R Kurzawinski in
Google Scholar
PubMed
Department of Clinical Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
Search for other papers by Mark N Gaze in
Google Scholar
PubMed
advised in these patients as they will require radioiodine therapy. Management of patients who will require specific radiation protection (for example pregnant mothers) should be by an experienced paediatric molecular radiotherapy service. Neck
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Victoria Byrd in
Google Scholar
PubMed
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Ted Getz in
Google Scholar
PubMed
Search for other papers by Roshan Padmanabhan in
Google Scholar
PubMed
Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA
Search for other papers by Hans Arora in
Google Scholar
PubMed
Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
Search for other papers by Charis Eng in
Google Scholar
PubMed
longitudinal Molecular Mechanisms of Cancer study (protocol 8458-PTEN) with identified pathogenic germline mutations in the PTEN gene. From this cohort, we enrolled 17 individuals with a history of component cancers and 15 without a history of cancer. History
Search for other papers by Jaydira Del Rivero in
Google Scholar
PubMed
Search for other papers by Josh Mailman in
Google Scholar
PubMed
Search for other papers by Michael W Rabow in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by Sarah Creed in
Google Scholar
PubMed
Search for other papers by Hagen F Kennecke in
Google Scholar
PubMed
Search for other papers by Janice Pasieka in
Google Scholar
PubMed
Search for other papers by Jennifer Zuar in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
Search for other papers by Lauren Fishbein in
Google Scholar
PubMed
part of palliation for SI-NET patients with MF. Other treatments for NETs, including telotristat ethyl, molecularly targeted agents, and peptide receptor radionuclide therapy, may delay the onset of MF. Still, their role in the acute symptomatic
Search for other papers by E Baudin in
Google Scholar
PubMed
Search for other papers by J Capdevila in
Google Scholar
PubMed
Search for other papers by D Hörsch in
Google Scholar
PubMed
Search for other papers by S Singh in
Google Scholar
PubMed
Search for other papers by M E Caplin in
Google Scholar
PubMed
Search for other papers by E M Wolin in
Google Scholar
PubMed
Search for other papers by W Buikhuisen in
Google Scholar
PubMed
Search for other papers by M Raderer in
Google Scholar
PubMed
Search for other papers by E Dansin in
Google Scholar
PubMed
Search for other papers by C Grohe in
Google Scholar
PubMed
Search for other papers by D Ferone in
Google Scholar
PubMed
Search for other papers by A Houchard in
Google Scholar
PubMed
Search for other papers by X-M Truong-Thanh in
Google Scholar
PubMed
Search for other papers by D Reidy-Lagunes in
Google Scholar
PubMed
Search for other papers by the SPINET Study Group in
Google Scholar
PubMed
score of 0 or 1. Patients were excluded if they had received previous SSA treatment, more than two lines of chemotherapy (cytotoxic, molecular targeted therapy, or interferon-alpha) for TCs/ACs, or chemotherapy in the 4 weeks before randomization, or if